General
Preferred name
vactosertib
Synonyms
EW-7197 ()
TEW-7197 ()
EW-7197 (Hydrochloride) ()
TEW-7197 (Hydrochloride) ()
Vactosertib (Hydrochloride) ()
TEW 7197 ()
Vactosertib (TEW-7197) ()
P&D ID
PD021555
CAS
1352608-82-2
1352610-25-3
Tags
available
drug candidate
Drug indication
Myeloproliferative neoplasm
Urothelial carcinoma
Solid tumour/cancer
Myelodysplastic syndrome
Drug Status
investigational
Max Phase
2.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
The discovery of vactosertib (EW-7197) is reported in where it is compound 12b. EW-7197 acts as in inhibitor of transforming growth factor beta receptor 1B (TGFβR1; ALK5) and activin A receptor type IB (ACVR1B; ALK4). The compound is potent, selective, and orally bioavailable, and exhibits experimental anti-tumour activity.
(GtoPdb)
DESCRIPTION
The discovery of EW-7197 is reported in where it is compound 12b. EW-7197 acts as in inhibitor of transforming growth factor beta receptor 1B (ALK5) and activin A receptor type IB (ALK4). The compound is potent, selective, and orally bioavailable, and exhibits experimental anti-tumour activity. Proposed INN is vactosertib.
DESCRIPTION
The discovery of EW-7197 is reported in where it is compound 12b. EW-7197 acts as in inhibitor of transforming growth factor beta receptor 1B (ALK5) and activin A receptor type IB (ALK4). The compound is potent, selective, and orally bioavailable.
DESCRIPTION
Vactosertib (EW-7197) acts as in inhibitor of transforming growth factor beta receptor 1B (ALK5) and activin A receptor type IB (ALK4). The compound is potent, selective, and orally bioavailable, and exhibits experimental anti-tumour activity.
(PKIDB)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
19
AdooQ Bioactive Compound Library
Cayman Chemical Bioactives
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugMAP
EU-OPENSCREEN Bioactive Compound Library
EUbOPEN Chemogenomics Library
Guide to Pharmacology
LINCS compound set
PKIDB
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
29
Molecular Weight
399.16
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
2
Rotatable Bonds
5
Ring Count
5
Aromatic Ring Count
5
cLogP
4.24
TPSA
83.79
Fraction CSP3
0.09
Chiral centers
0.0
Largest ring
6.0
QED
0.46
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
TGF-¦Â Receptor
ALK1
ALK2
ALK3
ALK4
ALK5
TGF-??Receptor
ACVR1B, TGFBR1
TGF-β Receptor
Pathway
Angiogenesis
Tyrosine Kinase/Adaptors
TGF-beta/Smad
MOA
TGF beta receptor inhibitor
Recommended Cell Concentration
100 nM
Source data
